Monitor Q3 2026 patient treatment volume and revenue recognition rate — the two failed batches in Q2 highlight manufacturing yield risk. The CMS NTAP designation is a positive structural catalyst for hospital adoption and Medicare patient access, but the company's cash runway (approx. 4-5 quarters at current burn) and path to profitability remain key overhangs. Watch for QTC activation pace and biopsy-to-treatment conversion rates as leading indicators of commercial trajectory.
Price Chart
Executive Summary
Abeona reported Q2 2026 net product revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026, driven by five patient treatments. Net loss widened to $(20.2)M ($(0.35)/share) vs $(17.1)M in Q1, primarily due to a $(7.2)M non-cash charge from the change in fair value of warrant liabilities. Cash burn continues with cash and investments declining to $146.8M from $191.4M at year-end 2025. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst for hospital adoption, but the company remains pre-profitability with no analyst consensus provided for Q2 to gauge surprise magnitude.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue $11.4M, up 31% QoQ from $8.7M in Q1 2026
- Five patients treated in Q2; three additional treatments in Q3 to-date; 12 total since launch
- Net loss $(20.2)M or $(0.35)/share vs $(17.1)M or $(0.30)/share in Q1 2026
- Cash, cash equivalents and short-term investments $146.8M as of June 30, 2026, down from $191.4M at Dec 31, 2025
- CMS granted NTAP status for ZEVASKYN effective October 1, 2026, supporting hospital adoption
- QTC network expanded to seven sites; Cincinnati Children's activated in Q3 2026
- Revenue not recognized for two patients due to low manufacturing yield or lot release failures
- R&D expenses $5.0M in Q2 vs $9.6M in Q1 (Q1 included $7.0M one-time in-licensing fee for ABO-701)
- SG&A expenses $15.8M in Q2 vs $19.5M in Q1, reflecting fewer engineering runs and training costs
Financial Impact
Q2 net product revenue $11.4M; net loss $(20.2)M; cash burn $44.6M in H1 2026
Risk Factors
- Manufacturing yield failures — two batches did not meet release specs or had low yield, preventing revenue recognition
- Cash burn rate — $44.6M consumed in H1 2026; $146.8M remaining provides limited runway without additional financing
- Commercial adoption still early — only 12 total treatments since launch; scalability of QTC network unproven
- Dependence on single product ZEVASKYN; ABO-701 still preclinical with IND filing expected H2 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037575 |
| Document: form8-k.htm | 0001493152-26-037575 |
| Document: 0001493152-26-037575-index-headers.html | 0001493152-26-037575 |
| Document: 0001493152-26-037575-index.html | 0001493152-26-037575 |
| 8-K Data (Synthetic) | 0001493152-26-037575 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access